Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP303 PK/PD in Healthy Chinese Participants
NCT06308523Phase 1Completed
- Sponsor
- Alebund Pharmaceuticals
- Start
- Mar 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AP-303 in autosomal dominant polycystic kidney disease (ADPKD) and diabetic kidney disease (DKD) (4 arms), sponsored by Alebund Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration (Cmax), Time to Maximum Plasma Concentration (Tmax) and 16 more. Started Mar 2024; status: completed.
02
Drugs
AP-303
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT06308523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06308523.